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Introduction
The treatment of headache patients is often complicated by
substance abuse that may progress to a drug dependency.
Patients with daily or near-daily headaches often describe a
history of daily medication consumption.
The pathogenesis of analgesic-induced headache is not
clearly understood, although there is evidence to suggest
involvement of serotonin (5HT) in this process [1]. Hering
J Headache Pain (2000) 1:S21–S26
© Springer-Verlag 2000
Relevance of analgesic abuse 
in the maintenance of chronic headaches
Luigi Alberto Pini
Giuliano Relja
Abstract The mechanisms facilitat-
ing or prompting the chronicization
of headache and the increased use of
analgesics are still unknown and
under debate. It is not clear whether
the daily use of analgesics in chronic
headaches is to be considered a habit
or a therapeutic need. Recently, our
group showed that items more
involved in chronicization of
headaches were the onset as
migraine and the use of analgesics,
namely mixture compounds. One of
the most important features in induc-
ing habit behavior is the reward: in
this illness, does the reward come
from the pain relief or from the
intrinsic euphoric activity of the
drugs, or does it depend on a more
complex behavior? Although the
system of neurotransmitters involved
in the biology of reward is complex,
at least four neurotransmitters are
known to be involved at several sites
in the brain: serotonin in the hypo-
thalamus, the enkephalins (opioid
peptides) in the ventral tegmental
area, DOPA in nucleus accumbens,
and the inhibitory neurotransmitter
GABA in the ventral tegmental area
and the nucleus accumbens. In a nor-
mal person, these neurotransmitters
work together in a cascade of excita-
tion or inhibition between complex
stimuli and complex responses lead-
ing to a feeling of well being, the
ultimate reward. In the cascade theo-
ry of reward, a disruption of these
intercellular interactions results in
anxiety, anger and other “bad feel-
ings” or in a craving for a substance
that alleviates these negative emo-
tions. Probably, serotonin plays a
pivotal role in migrane pathogenesis,
thus drugs alleviating migraine
should act through this neurotrans-
mitter. Therefore, these drugs when
used in specific settings, as compul-
sive behavior, may contribute to the
development of mechanisms of
reward linked to its use and may
induce habit behavior. Epidemiologi-
cal studies support this idea. The
chronic use of barbiturate- or opiate-
containing analgesics is preferred by
patients who daily consume drugs
and who suffer from daily
headaches. 
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et al. [2], in 1993, reported a reduction in whole blood 5HT
in patients with  analgesic rebound headache which was
normalized on discontinuing the analgesics. This rise in
5HT level in the whole blood paralleled the improvement in
headache frequency. Patients with analgesic-induced
headaches have lower basal content of platelet 5HT; their
platelets exhibit reduced 5HT uptake when incubated with
excess of the amine, and have a greater density of 5HT2-
receptors on the plasma membrane than migrainous patients
without analgesic-reduced headache [1]. These observations
suggest that chronic analgesic overuse interferes with the
intrinsic pain modulatory system by depletion of 5HT and
consequently by up-regulation of its post-synaptic recep-
tors. Therefore, it is likely that analgesic-induced headache
is, at least partly, due to defective mechanisms of 5HT
uptake caused by analgesic use [3].
The mechanisms facilitating or prompting the chroni-
cization of headache and/or the increased use of analgesics
are still unknown and under debate. It is not clear whether
the daily use of analgesics is to be considered a habit or
simply belongs to therapeutic needs. 
Recently, our group showed that items significantly
involved in chronicization of headaches were the onset as
migraine and the use of analgesics, namely mixture com-
pounds. When we compared the evolution of single patients
with respect to analgesic consumption, we identified a
strong linkage between the use of mixtures (barbiturate or
prochlorperazine-containing drugs) during the follow-up
period and the maintenance of this habit along time, where-
as only half of patients using single preparations maintained
this preference. By contrast about 90% of patients using
mixtures daily did not turn to single compounds.
The constancy in preference for mixtures, both barbitu-
rate and percholperazine-containing compounds, suggests
an addictive effect of small doses of these central-acting
drugs in maintaining daily drug use.
The International Headache Society (IHS) classifies
drugs able to induce abuse and headache. A number of these
drugs show antimigraine activity (e.g. NSAIDs, ergotamine)
and drug-dependence habit, such as theobromine, caffeine
and amphetamine [4].These drugs act by activating the cen-
tral serotonergic system. Opiates and NSAIDs also act
through the serotonergic system, mainly with regard to their
antinociceptive activity [5]. 
Ergot derivatives and triptans act by stimulating 5HT
receptors in the central nervous system (CNS) and are con-
sidered to be drugs able to caused drug-induced headaches
[6]. The abuse potential of sumatriptan was tested by
Sullivan et al. [7] in 1992. This drug was found to be psy-
choactive, discriminated from placebo, and produced a
dose-related decrease in euphoria scores. Elevated scores on
measures of apathetic sedation and disliking were found,
whereas sumatriptan lacked identification as a prototypic
drug of abuse. This study suggested that sumatriptan had
only a low abuse potential.
Because the most important feature in inducing habit
behavior is the reward, in the case of abuse of analgesics by
chronic headache sufferers the main question is: does the
reward come from the relief of pain or from the euphoric
activity of the drug, or is the behavior more complex?
Therefore, reward mechanisms should be an important step
in maintaining drug abuse. We outline in this paper the link-
age between the serotonergic system in the brain and its
potential role in reward mechanisms.
The reward mechanism
The reward mechanism is a complex reaction to a variety of
external and internal stimuli that interact with a number of
CNS structures, thereby inducing changes that influence
behavior [8]. The pleasure and reward system in the brain
was discovered by accident in 1954. The American psychol-
ogist James Olds was studying the rat brain’s alerting
process, when he mistakenly placed the electrodes in a part
of the limbic system, a group of structures deep within the
brain that are generally believed to play a role in emotions
[9]. When the brain was wired so that the animal could stim-
ulate this area by pressing a lever, Olds found that the rats
would press the lever almost nonstop, as many as 5000 times
per hour. The animals would stimulate themselves to the
exclusion of everything else except sleep. They would even
endure tremendous pain and hardship for an opportunity to
press the lever. Olds had clearly found an area in the limbic
system that provided a powerful reward for these animals.
Natural rewards preferentially stimulate dopamine trans-
mission in the nucleus accumbens shell. This effect under-
goes adaptive changes (e.g. one-trial habituation, inhibition
by appetitive stimuli) that are consistent with a role of
nucleus accumbens shell dopamine in associative reward-
related learning [10]. Experimental studies with a variety of
paradigms confirm this role. Resistance to habituation
allows drugs to activate dopamine transmission in the shell
non-decrementally upon repeated self-administration. It is
hypothesized that this process abnormally strengthens stim-
ulus-drug associations, thus resulting in the attribution of
excessive motivational value to discrete stimuli or contexts
predictive of drug availability. Addiction is therefore the
expression of the excessive control over behavior acquired
by drug-related stimuli as a result of abnormal associative
learning following repeated stimulation of dopamine trans-
mission in the nucleus accumbens shell.
Although the system of neurotransmitters involved in
the biology of reward is complex, a number of other neuro-
transmitters are known to be involved at several sites in the
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brain: serotonin in the hypothalamus, the enkephalins (opi-
oid peptides) in the ventral tegmental area and the nucleus
accumbens, and the inhibitory neurotransmitter GABA in
the ventral tegmental area and the nucleus accumbens [8,
11]. Studies examining the effect of selective agonist and
antagonist drugs administered systemically have indicated
that multiple neurotransmitters are involved, including
dopamine, serotonin, acetylcholine, glutamate, GABA, and
various peptides [12]. Direct microinjection studies have
also provided crucial evidence indicating that, in addition to
the mesolimbic dopamine system, other structures play a
role in drug reward, including the ventral pallidum, amyg-
dala, hippocampus, hypothalamus, and pedunculopontine
tegmental nucleus. GABAergic circuitry descending from
the nucleus accumbens to the pedunculopontine tegmental
nucleus via the ventral pallidum appears to be especially
important in directing the behavioral sequelae associated
with reward produced by various drugs of abuse. However,
activation of the reward circuitry is achieved differently for
various drugs of abuse. 
In a normal person, these neurotransmitters work togeth-
er in a cascade of excitation or inhibition – between complex
stimuli and complex responses – leading to a feeling of well
being, the ultimate reward [11, 13]. In the cascade theory of
reward, a disruption of these intercellular interactions results
in anxiety, anger and other “bad feelings” or in a craving for
a substance that alleviates these negative emotions (Fig. 1).
Serotonin in the reward system 
5HT1 recepors play a relevant role in dependence mecha-
nisms [14]. These authors showed that activation of 5-HT1B
receptors in the nucleus accumbens reduced amphetamine-
induced enhancement of responding for conditioned reward.
Moreover, they showed that increasing 5-hydroxytrypta-
mine (5HT) activity attenuated responses for conditioned
reward (CR), and that d-amphetamine has a response-poten-
tiating effect on this behavior [15]. Serotonin depletion
selectively enhances responding for CR. Although 5HT
depletion did not potentiate the effects of d-amphetamine, it
was suggested that CRs activate the mesolimbic dopamine
system, and that removal of an inhibitory influence of 5HT
on the activity of this system results in increased responding
for CR in 5,7-dihydroxytryptamine-treated rats.
Rogers et al. [16] suggested that reduction in central
serotonin leads to altered neuromodulation of the cortical
and subcortical regions (e.g. orbitofrontal cortex, striatum
and anterior temporal structures) that mediate important
aspects of associative learning whereby exteroceptive stim-
uli acquire altered incentive motivational value. On the
other hand, facilitation of catecholamine neurotransmitters
may disrupt the allocation of attention between relevant and
irrelevant features of the environment, perhaps through
altered modulation of the dorsolateral prefrontal cortex.
5HT3 receptors may play a role in reward circuits by
modulating the release of dopamine on mesolimbic ways.
Mice that overexpress 5HT3 receptors in both cortex and
forebrain regions have been developed by placing the gene
under the control of the Ca++calmodulin-kinase IIα promot-
er [17]. Overexpression of 5HT3 receptors reduced alcohol
consumption in transgenic mice, showing the importance of
these receptors in reward behavior. Activation of 5HT3
receptors, the only serotonergic receptor linked to K+ and
Na+ ion channels, changes rapidly the membrane polariza-
tion and depletes the neurotransmitter. Antagonists of these
receptors reduce mesolimbic dopamine and reduce the psy-
chomotor activity of dopaminergic drugs. In fact, 5HT3
antagonists inhibit withdrawal symptoms of a number of
drugs, such as cocaine, amphetamine, morphine and
diazepam, but not of alcohol [18]. The experimental evi-
dence suggests that 5HT3 antagonists act through specific
neurotransmitter pathways and not through non-specific
modifications. 
Ondansetron, a classic antagonist of 5HT3 receptors,
does not modify behavior induced by nicotine [19].
The role of 5HT4 receptors is not well established,
whereas these receptors are located in cerebral areas rich in
dopamine receptors. The 5HT4 antagonist SB204070-A did
not modify motor behavior in amphetamine- and nicotine-
treated rats, thereby excluding a role of this receptor in the
motor behavior induced by these drugs [20].
Fig. 1 Structures deep within the limbic system play a crucial role in
the expression of emotions and the activity of the reward system of
the brain. The experience of pleasure and the modulation of reward
are based on a reward “cascade,” a chain of neurons within the lim-
bic system that interact through various signaling molecules, or neu-
rotransmitters. We propose that a biochemical deficiency in one or
more of these neurons or signaling molecules can supplant an indi-
vidual’s feeling of well being with anxiety, anger or a craving for a
substance that can alleviate the negative emotions
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Analgesic abuse
An alteration in serotonin concentration has been found in
patients with chronic daily headache (CDH) linked with
abuse of analgesic drugs, as has been the up-regulation of
5HT2 platelet receptors, which has been correlated with
chronicization of headache [1]. This was correlated with
NO and cGMP production and a reduction in platelet sero-
tonin levels. The morphological modifications in platelets
and biochemical evaluations lead to the hypothesis  that the
NO-related intracellular mechanisms operating only in
platelets of migraine patients are more accentuated in
chronic daily headaches patients owing to chronicization
from a previous history of migraine without aura. Whether
changes in serotonin and NO metabolism in platelets of
CDH patients reflect similar changes in CNS is under
debate. However, it has often considered that platelets can
be considered to be a peripheral model of monoaminergic
neurons, and a similar alteration of the central serotonergic
pathway in CDH  patients cannot be excluded [21].
Nicolodi et al. [22] reported that chronic treatment with
5HT agonists such as methysergide and propranolol ame-
liorate chronic hadaches; by contrast the use of sumatriptan
and ergotamine worsened the clinical picture. These
authors concluded by stressing the possible 5HT supersen-
sitivity that characterizes these patients.
In 1996, Schnider et al. [23] in a 5-year follow-up of 38
patients with chronic headache found a close correlation
between the frequency of headache and the following:
duration of drug abuse, the intensity of headaches and the
number of tablets taken per month. 
In a 4-year follow-up at the Headache Center of
Modena (Italy) (unpublished data), we found  that most
patients preferred the use of mixtures, both barbiturates and
percholperazine-containing compounds. This preference
suggests that small doses of central-acting drugs contribute
to the reinforcement of drug abuse (Table 1).
Life events indirectly influence the frequency and the
intensity of headache, thus modifying behavior and chang-
ing the relationships among drug, pain and patient. Finally,
a reward emerges from the resolution of pain [24].
In a large study on psychiatric comorbidity in patients
with tension-type headache, chronic patients showed high
generalized anxiety and psychosocial stress. This empha-
sizes the need for a systematic investigation of psychiatric
comorbidity in these patients [25].
Some patients experience rebound headache from
overuse of analgesics and other headache medications.
Sumatriptan and dihydroergotamine are more expensive
than other migraine agents but have distinct therapeutic
advantages in patients with moderate to severe headaches
[26].
In 1999, Zed et al. [27] reviewed a number of therapies
for acute management of migraine with intervallar
headache (MIH), although no rigorously conducted clinical
trials were identified. Therapies evaluated included abrupt
withdrawal of analgesics, initiation of dihydroergotamine,
nonsteroidal antiinflammatory agents, methylergonovine,
dihydroergotamine, sumatriptan, amitriptyline, dexametha-
sone, piracetam, prothipendyl, and valproate. Epidemiolo-
gy, diagnosis, clinical features, pathophysiology, and long-
term prognosis of therapy were discussed and therapeutic
guidelines were offered. Serotonin agonists for the treat-
ment of chronic daily headaches have been studied and
some positive results have been obtained in follow-ups last-
ing some months [28, 29]. 
There is evidence from animals that supports the role of
serotonin in nociception. The antinociceptive activity of
some NSAIDs has been proved  to be mediated by the sero-
tonergic system [5]. The same drugs are also used widely in
the treatment of headaches and migraine attacks. Evidence
of influence of these drugs on the opiatergic system has
also been reported. These data suggest possible links
between the serotonergic system and the endogenous opi-
Table 1 Trends in drug abuse in 90 chronic daily headache sufferers through a 4-year follow-up by analgesic type
Abusers at study entry, n (%) At 4-year follow-up    
Abusers, n Non-abusers, n (%)a
Optalidonb 22  (24) 15 7 (32)  
Difmetrèc 17  (19) 11    6 (35)  
Mixturesd 7    (8) 5      2 (29)  
NSAIDs 35    (39) 17    18 (52) 
Triptans 3      (3) 2      1 (33)  
Ergot 6      (7) 3      3 (50)  
Total 90    (100) 54   36 (40)  
a Percent of patients that were no longer abusers after 4 years, for the respective drug; b Optalidon: phenazone + caffeine + butalbital;
c Dilfmetrè: indomethacin + caffeine + perchlorperazine; d Mixtures: drugs containing paracetamol of aspirin plus caffeine or metilmor-
phine or metoclopramide
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atergic system, well known to be the main system involved
in final modulation of pain control, and on the reward
mechanism. In this way the same neurotransmitters play a
role in modulating nociception and reward mechanism.
This observation suggests that drugs acting on these path-
ways can induce or favor the reward behavior.
Conclusions
The main problem with the role of daily analgesic use (or
so-called abuse) in the maintenance of chronic headache
depends on the lack of animal models in which to evaluate
the relationship between drug use and headache. On the
other hand clinical well controlled trials are lacking in liter-
ature. Objective and ethical reasons do not allow the design
of placebo-controlled trials  to measure the habit potency of
antimigraine drugs in headache sufferers. Moreover, there is
some confusion in the terms medication misuse, overuse
and abuse-headaches. Mathew [3] in 1998 defined this clin-
ical picture as “a self-sustaining, rhythmic, headache-med-
ication cycle characterized by daily or near daily headache
and irresistible and predictable use of immediate relief med-
ications”. This sentence contains an ambiguous definition:
“the only means of relieving headache attacks”  means that
the headache attack is on, or should we understand a pre-
ventive therapy assumed by the patients for an “imminent”
or “forecast probable attack”? In the first case the drug
assumption is correct because there is a medical indication
to assume analgesic drugs when headache is starting. In the
second one the range of variability in the decision to assume
or not the drug, to reach an actual preventive therapy of that
attack depends in large amount on the emotive status of the
patient. In this case it can be considered, when the time and
the behavior of the drug assumption are always the same, a
compulsive behavior and speculate on a possible abuse.
So the abuse must be considered as a compulsive behav-
ior in some way not strictly linked to the type of used anal-
gesic and related more to “how” the drug is assumed than
“what” drug is assumed.
There is no evidence of addictive personality in these
patients [30]. Sensation-seeking behavior auditory poten-
tials are lacking in these patients with chronic headache [31]
A number of chronic diseases are associated with pro-
longed daily or near daily assumpion of analgesic drugs,
often belonging to the NSAID pharmacological class. In
these patients, for example in patients suffering from chron-
ic arthritis, there were no reports of increased incidence of
headache or the existence of habit due to the analgesic use;
by contrast analgesic assumption is recommended and the
withdrawal of analgesic is evaluated as non-compliance by
physicians [32].
In the follow-up performed in our center, the type of
abused drugs were constant over time. After 4 years, the
percent of drugs that were used daily was not statistically
modified, whereas the  patients using drugs containing
CNS-active compounds maintained the use more than
patients assuming simple analgesics. 
Reward behavior is a widespread mechanism  involving
many neurotransmitters and thus is influenced by a large
number of drugs, as by a large number of socio-economic
conditioning behaviors. In this respect, pharmacologically
speaking, drugs used for headache and migraine relief can
modify these behaviors. Moreover, the mental significance
of head “ache” and the lifestyles related to the presence and
the management of migraine and headaches are quite differ-
ent within patients. So only in migraine sufferers we can
identify a clinical picture, so-called analgesic abuse, where
the headache disappears when the drugs used to treat the
pain are discontinued.  In this way we observe a difference
between the use of analgesics in patients suffering from
chronic arthritis and patients suffering from chronic
headaches.
Finally, some reports suggest the chronic sufferers
exhibit a compulsive mode of assumption of antimigraine
analgesics, i.e. time-scheduled assumption, preventive
assumption of analgesic because of a forecast of headache
linked to a particular life event (e.g. trip, job, meeting, din-
ner). This fact may underlie the role of drug significance in
abuse or addictive behavior present in chronic headache
patients.
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